ADAGIO MEDICAL HOLDINGS, INC. Research and Development Expense
ADAGIO MEDICAL HOLDINGS, INC. (ADGM) reported Research and Development Expense of $2.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- ADAGIO MEDICAL HOLDINGS, INC. research and development expense for the quarter ending 2026-06-30 was $2.45M, a 24.30% increase year-over-year.
- ADAGIO MEDICAL HOLDINGS, INC. research and development expense for the quarter ending 2026-03-31 was $2.74M, a 25.09% decline year-over-year.
- ADAGIO MEDICAL HOLDINGS, INC. research and development expense for the quarter ending 2025-12-31 was $2.23M.
- ADAGIO MEDICAL HOLDINGS, INC. research and development expense for the quarter ending 2025-09-30 was $2.77M.
- ADAGIO MEDICAL HOLDINGS, INC. research and development expense for fiscal 2025 was $10.64M.
- ADAGIO MEDICAL HOLDINGS, INC. research and development expense for fiscal 2023 was $15.40M.
| Period end | Research and Development Expense 1 month | Research and Development Expense 2 month | Research and Development Expense 3 month | Research and Development Expense 5 month | Research and Development Expense 6 month | Research and Development Expense 7 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.45M 10-Q · filed 2026-08-11 | $5.19M 10-Q · filed 2026-08-11 | $7.43M derived: sum of 3 quarters · filed 2026-08-11 | $10.20M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $2.74M 10-Q · filed 2026-05-12 | $4.98M derived: sum of 2 quarters · filed 2026-05-12 | $7.75M derived: sum of 3 quarters · filed 2026-05-12 | $9.72M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $5.01M derived: sum of 2 quarters · filed 2026-03-27 | $6.98M derived: sum of 3 quarters · filed 2026-08-11 | $10.64M 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | $2.77M 10-Q · filed 2025-11-12 | $4.75M derived: sum of 2 quarters · filed 2026-08-11 | $8.40M 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | $1.97M 10-Q · filed 2026-08-11 | $5.63M 10-Q · filed 2026-08-11 | ||||||
| 2025-03-31 | $3.66M 10-Q · filed 2026-05-12 | |||||||
| 2024-12-31 | $4.63M 10-K · filed 2026-03-27 | |||||||
| 2024-09-30 | $1.22M 10-Q · filed 2025-11-12 | |||||||
| 2024-07-30 | $1.25M 10-Q · filed 2025-11-12 | $7.58M 10-K · filed 2026-03-27 | ||||||
| 2024-06-30 | $2.87M 10-Q · filed 2025-08-14 | $6.33M 10-Q · filed 2025-08-14 | $8.11M derived: sum of 3 quarters · filed 2025-08-14 | $12.53M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $3.47M 10-Q · filed 2025-05-15 | $5.24M derived: sum of 2 quarters · filed 2025-05-15 | $9.66M derived: sum of 3 quarters · filed 2025-05-15 | |||||
| 2023-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $6.19M derived: sum of 2 quarters · filed 2025-03-27 | $15.40M 10-K · filed 2025-03-27 | |||||
| 2023-09-30 | $4.42M 10-Q · filed 2024-11-14 | $13.63M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |